Astrazeneca (AZN) Long-Term Debt Repayments (2019 - 2026)

Astrazeneca has reported Long-Term Debt Repayments over the past 10 years, most recently at -$2.0 million for Q1 2026.

For Q1 2026, Long-Term Debt Repayments rose 50.0% year-over-year to -$2.0 million; the TTM value through Mar 2026 reached -$2.0 billion, up 56.4%, while the annual FY2025 figure was -$2.0 billion, 56.38% up from the prior year.
Long-Term Debt Repayments for Q1 2026 was -$2.0 million at Astrazeneca, up from -$2.0 billion in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at -$2.0 million in Q1 2026 and troughed at -$2.6 billion in Q2 2024.
A 5-year average of -$872.9 million and a median of -$12.0 million in 2025 define the central range for Long-Term Debt Repayments.
Biggest five-year swings in Long-Term Debt Repayments: plummeted 50000.0% in 2023 and later skyrocketed 99.8% in 2025.
Year by year, Long-Term Debt Repayments stood at -$1.3 billion in 2022, then fell by 12.05% to -$1.4 billion in 2023, then soared by 99.64% to -$5.0 million in 2024, then crashed by 40080.0% to -$2.0 billion in 2025, then skyrocketed by 99.9% to -$2.0 million in 2026.
Business Quant data shows Long-Term Debt Repayments for AZN at -$2.0 million in Q1 2026, -$2.0 billion in Q4 2025, and -$4.0 million in Q3 2025.

Peer Comparison